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Abstract  
Introduction 
Gene expression is widely used for the characterization of breast cancers. Variability due 
to tissue heterogeneity or measurement error or systematic change due to peri-surgical 
procedures can affect measurements but is poorly documented. We studied the 
variability of global gene expression between core-cuts of primary ER+ breast cancers 
and the impact of delays to tissue stabilization due to sample x-ray and of diagnostic 
core-cutting. 
Methods 
Twenty-six paired core-cuts were taken immediately after tumour excision and up to 90 
minutes delay due to sample x-ray; 57 paired core-cuts were taken at diagnosis and 2 
weeks later at surgical excision. Whole genome expression analysis was conducted on 
extracted RNA. Correlations and differences were assessed between the expression of 
individual genes, gene-sets/signatures and intrinsic subtypes. 
Results 
Twenty-three and 56 sample pairs, respectively, were suitable for analysis. The range of 
correlations for both sample sets were similar with the majority being >0.97 in both. 
Correlations between pairs for 18 commonly studied genes were also similar between the 
studies and mainly with Pearson correlation coefficients >0.6 except for a small number 
of genes which had a narrow-dynamic range (e.g. MKI67, SNAI2). There was no 
systematic difference in intrinsic subtyping between the first and second sample of either 
set but there was c.15% discordance between the subtype assignments between the 
pairs, mainly where the subtyping of individual samples was less certain. Increases in 
the expression of several stress/early-response genes (e.g. FOS, FOSB, JUN) were found 
in both studies and confirmed findings in earlier smaller studies. Increased expression of 
IL6, IGFBP2 and MYC (by 17%, 14% and 44%, respectively) occurred between the 
samples taken 2-weeks apart and again confirmed findings from an earlier study. 
Conclusions 
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There is generally good correlation in gene expression between pairs of core-cuts except 
where genes have a narrow dynamic range. Similar correlation coefficients to the 
average gene expression profiles of intrinsic subtype, particularly LumA and LumB, can 
lead to discordances between assigned subtypes. Substantial changes in expression of 
early response genes occur within an hour after surgery and in IL6, IGFB2 and MYC as a 
result of diagnostic core-cut biopsy. 
 
Trial Registration 
Trial Number CRUK/07/015. Study start date September 2008. 
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Introduction 
Molecular analyses of primary breast cancer for both research and patient management 
are now commonplace. Measurements may be made on diagnostic core-cut biopsies or 
surgical excisions that frequently comprise a very small fraction of the tumour. In so-
called window-of-opportunity studies patients are exposed to medical therapy between 
diagnosis and surgery [1] and comparisons are made between samples taken at both 
time points. Valid interpretation of these studies depends on knowledge of any variability 
or systematic changes in the respective biomarkers that occur in the absence of 
treatment. Variability/heterogeneity may lead to false rejection of a true effect while 
systematic differences between diagnostic and surgical specimens may lead to artifactual 
changes being falsely ascribed to an intervention. For example, we have previously 
described the highly significant impact of specimen type (core-cut vs excision) on pAKT 
and pERK1/2 staining [2]. Pre-treatment/post treatment comparison of biomarkers 
might also be affected by the taking of the diagnostic biopsy and changes due to cold 
ischemia between resection and tissue stabilization/fixation. 
The effect of cold ischemia time has been studied in small cohorts of breast cancer with 
up to 24 hours elapsed time before fixation, snap freezing or placement in RNA later [3-
5]. No studies have directly examined the impact of the short time delay (20-60 
minutes) resulting from sending specimens for x-ray, a frequent practise during breast 
cancer surgery to ensure the removal of the lesion (e.g. non-palpable mass, 
calcifications) and/or to check for adequate surgical margins, even in clinically palpable 
tumours. A small number of studies have evaluated gene expression changes over a 
longer period of time between biopsies [6-8]. For example, Jeselsohn identified 14 
genes, including 9 immune-related that differed between core cuts and excision taken 
from 21 patients 6-65 days apart (mean 30 days). 
Our primary objectives were to use genome-wide expression profiling to determine more 
comprehensively the variability and systematic changes in the expression of genes or 
pre-specified genesets or subtype classifications (i) between two core biopsies taken (A) 
immediately after excision and (B) after sample x-ray and (ii) between diagnostic core 
biopsies (D) and surgical core biopsies (S) two weeks later in the absence of any 
intervention. 
 
Patients and Methods 
Patients and tissues 
Study I. To answer the first objective we accessed tissues collated from a previously 
published study [2]. Core cut biopsies (14-gauge needle) were taken from 26 surgical 
specimens and placed in RNAlater immediately after resection (sample A) and again 
after X-ray of the excised tumour (sample B). The time elapsed between samples A and 
B was recorded in the surgical report form. 
Study II. To answer the second objective we accessed tissues from the no-treatment arm 
of The PeriOperative Endocrine Therapy - Individualising Care (POETIC) trial that 
randomized post-menopausal patients with primary ER+ breast cancer from 120 UK 
centres (2:1) to receive two weeks’ non-steroidal aromatase inhibitor (AI) or no-
treatment for two weeks prior to surgery[1, 9].  
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At least 1 RNA later stored sample was available from 33.5% (1493/4456) of patients or 
paired from 13.2% (589/4456) of patients of the poetic trial. 227 control samples were 
subjected to RNA extraction. Expression analyses were conducted when a pair of RNA 
extracts was available with RIN >4. This amounted to 57 pairs of samples from control 
patients taken at diagnosis (D) and surgery (S). 
 
Ethics statement 
Patient consent and ethics approval for the collection and analysis of breast cancer tissue 
samples was provided by the Royal Marsden Hospital for Study I. Ethical approval for 
POETIC (Trial Number CRUK/07/015) was provided by NRES Committee London –South 
East. 
 
Gene expression analysis, data pre-processing, data analyses and statistical methods. 
The detailed methodology is described in the supplementary information. 
In brief, extracted RNA was amplified, labeled and hybridized on Illumina global gene 
expression BeadChips. Illumina raw data was extracted using GenomeStudio software 
and transformed, normalized and batch-corrected. Paired samples were excluded from 
further analysis if their fraction of detected genes was <30% and probes were filtered 
out if they were not detected in any sample. Gene expression data from this study is de-
posited at GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73237) with 
accession number GSE73237 [10]. 
Entrez Gene ID was used as gene identifier in gene signatures. The HumanHT-
12_V4_0_R2_15002873_B annotation file was used to map the EntrezGeneIDs to the 
corresponding Illumina probe IDs. Gene signature scores were weighted averages. 
We evaluated three candidate gene sets: i) metagene wound healing signature [11]; ii) 
immune response metagene [12] and iii) 13 of the 14 genes identified as changing in the 
Jeselsohn study [6] (SNAI1 was not detected on the Illumina platform). We also studied 
the effects on 18 pre-specified genes that we selected as being particularly relevant to 
breast cancer from prior studies.   
Each tumour sample was classified into one of the five intrinsic subtypes based on the 
PAM50 classifier as described in the supplementary information. 
Pearson and Spearman correlations were used to assess the associations. Univariate 
paired or unpaired T-tests together with multivariate permutation tests were used to 
identify differentially expressed genes between the paired samples. The significantly 
differentially expressed genes were subjected to Ingenuity Pathway Analysis (IPA). The 
significance of the difference between 2 correlation coefficients obtained in study I and 
study II respectively was calculated using the Fisher r-to-z transformation [13]. 
GraphPad Prism 6 (Graphpad Software Inc.) was used for some of the statistical analyses 
in this study. 
 
Results 
Study I 
Sufficient RNA was available from 26 sample pairs with up to 90 minutes between 
samples A and B. Three pairs were excluded due to low fraction of detected genes, 
leaving 23 pairs with a time interval of 20 to 60 minutes (median 30) for downstream 
data analysis. Patient demographics are described in Table S1. 
 
Variability in gene expression between samples 
On hierarchical clustering 16 (70%) of the pairs clustered together (Figure 1A). The 
correlation of the gene expression for the 24,395 probes between samples A and B 
provides an overall assessment of the similarity of transcriptional profiles between the 
samples. The Pearson correlation coefficient r values ranged from 0.91 to >0.99 (Figure 
S1). Nine selected pairs in Figure S2 represent the range of variability: 3 sets of 3 pairs 
with a coefficient >0.99, 0.98 or 0.91-0.94. Correlation was also determined between 
paired expression levels of 18 pre-selected genes frequently reported in breast cancer 
(Table S2, Figure S2). The correlation was above >0.6 and highly statistically significant 
for all genes, except for MKI67 (r=0.35, p=0.10), SNAI2 (r=0.43, p=0.04) and PGR 
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(r=0.52, p=0.01) (Table 1). Upload of the full data set to GSE73237 [10] allows 
investigators to assess the correlation/variability of their genes of interest. 
 
Effect of time to fixation on gene expression 
Using class comparison method with False Discovery Rate (FDR) <5% no significant 
systematic differences in expression were found between samples A and B. However, 68 
genes had a p<0.005 and fold-change ≥1.25 (19 upregulated and 49 downregulated). 
Table 2 shows the top 8 of these genes ordered according to fold-change. The genes 
included early response (RGS1, RGS2), mitochondrial ATP synthase (ATP5C1) and stress 
response genes (DUSP1, FOSB). Ingenuity Pathway Analysis (IPA) of the 68 genes using 
Benjamini-Hochberg multiple testing corrected B-H p-value <0.05, identified 6 canonical 
pathways (Table S3A). These were mainly associated with metabolism or signalling, the 
most significant being oxidative phosphorylation (B-H p-value <0.005) and mitochondrial 
dysfunction (B-H p-value <0.005). The top networks identified also included metabolism 
(Table S3B). 
Change in expression of 116 genes correlated with time elapsed at p<0.005 (Table S4) 
but none were significant by their adjusted p-value. IPA of the 116 genes identified 28 
pathways that were significantly changed at p<0.05. The most significant were 
adipogenesis and mitochondrial dysfunction and the main networks were inflammation 
and metabolic disease (Tables S5 and S6). There were only 2 genes in common between 
the 68 (paired differences) and 116 (time elapsed) gene lists (SCD and AGPAT2 involved 
in fatty acid biosynthesis). 
Two of the 18 genes pre-selected as frequently reported showed a modest but 
statistically significant difference between samples A and B: BAG1 (mean 3% decrease, 
p=0.026), MAPT (mean 19% decrease, p=0.007) (Table 1). 
 
Analysis of candidate gene signatures and subtypes 
There were no significant differences in the Wound Healing signature score[11] or an 
immune-response metagene [12]. One of the 13 genes identified to be changing in the 
Jeselsohn study (IL6) showed an 11% increase (Wilcoxon matched-pairs signed rank 
test: p=0.014) between samples A and B [6]. 
Concordance for intrinsic subtypes between the sample pairs is shown in Table S7. The 
majority of these ER+ samples were Luminal, as expected. Three tumours showed 
discordance between samples at timepoint A and timepoint B: two Luminal A samples at 
time point A were scored as Luminal B or normal at time point B; one luminal B at time 
point A was rated as Luminal A at time point B. For each tumour, we calculated the 
numerical differences in the correlation coefficients to each of the LumA, LumB, and 
HER2-enriched centroids for each of samples A and B. As demonstrated in Figure S4A, 
these 3 cases with discordant intrinsic subtypes between the time points A and B had the 
median values of numeric difference between their LumA and LumB centroid correlations 
of 0.08 and 0.32 when compared with a median difference of 0.54 (95% C.I. 0.17-0.61) 
and 0.52 (95% C.I. 0.10-0.54) for the concordant samples at time points A and B 
respectively. 
 
Study II 
From the 57 pairs, 56 passed microarray QC analysis. Patient demographics are 
described in Table S1. 
 
Variability in gene expression between samples 
Seventy-three percent (41/56) of pairs clustered together on hierarchical clustering 
(Figure 1B). The correlation of the gene expression for the 32,332 probes between the 2 
samples ranged from 0.86 to >0.99 with a median correlation of 0.97 (Figure S5). As in 
study I, we evaluated the Pearson correlation coefficients between paired expression 
levels on 18 selected genes (Table S2, Figure S6). The correlation was above >0.6 
except for SNAI2 (r=0.48), MKI67 (r=0.52), and GPR160 (r=0.55). 
 
Gene expression comparison between baseline and surgery core 
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Thirty-nine genes (44 probes) were differentially expressed between biopsies D and S at 
FDR<5% and fold-change > 1.25. The 39 genes included 11 early response genes (FOS, 
JUN, RGS1), 6 stress response/immune genes (DUSP1, GADD45B, ATF3), 4 snoRNA 
(SNORD3C, SNORD3D), 4 haemoglobin (HBA2, HBB) and 5 genes associated to breast 
cancer progression (SIK1, TOB1, BHLHB2). Table 2B shows the top 8 genes identified. 
IPA analysis of the 39 genes identified 76 pathways affected (B-H p-value <0.05) (Table 
S8). Sixty per cent of the pathways identified were due solely to FOS and JUN. The most 
common enriched networks were proliferation and metabolism (Table S9). None of the 
18 pre-selected genes showed a statistically significant change between samples D and S 
(Table 1). 
 
Analysis of candidate gene signatures and subtypes 
There were no significant differences in the Wound Healing signature [11] or the immune 
response gene signature [12] between samples D and S. Of the 14 detected significantly 
differ genes described by Jeselsohn, two immune-related genes (IL6 and IGFPB2) and 
one other gene (MYC) were significantly increased in their expression in sample S by 
17%, 14%, and 44%, respectively. The changes in IL6, IGFBP2 and MYC did not 
significantly correlate with one another. 
Most samples were Luminal (Table S7B). Six of 39 (15%) tumours classified as Luminal 
A at baseline were classified as Luminal B at surgery, and four of 14 tumours classified 
as Luminal B at baseline were classified as Luminal A at surgery (29%, 4/14). Among 
the 14 cases with discordant intrinsic subtypes between the baseline and surgery, the 
median values of numeric difference between their Luminal A and Luminal B centroid 
correlations were 0.089 (95% C.I. 0.02-0.49) and 0.031 (95% C.I. 0.12-0.34) when 
compared with median values of 0.50 (95% C.I. 0.26-0.55) and 0.50 (95% C.I. 0.26-
0.53) for the concordant samples at baseline and surgery respectively (Figure S4B). 
Interestingly, the one LumB/HER2-E subtype discordant case also had <0.3 between the 
LumB/HER2-E centroids. 
 
Study I and Study II common genes 
Nine of the top 20 genes significantly different with FDR <5% and p<0.005 between 
samples D and S in study II were also significant with a p<0.05 between samples A and 
B in study I (Table S10). These included FOS, JUN and other early response genes. 
The changes in gene expression for IL6 and PGR were significantly different between 
Study I and II (Fisher’s r-to-z transformation, Table 1). IL6 expression correlated 
positively between the two samples within study I but not in study II. This was due to 
the difference between the D and S samples varying substantially between tumours: 
there were large increases in IL6 expression in a minority of samples while others 
remain largely unaffected (Figure 2). 
PGR expression was positively correlated between the paired samples in both studies. 
There was a significant tendency to an increase in study I (expression levels higher in 
timepoint B than A) and a decrease in study II (expression levels lower in timepoint S 
than D) that resulted in a marginally significant (p=0.024) heterogeneity between the 
studies. 
 
Discussion 
Multiple issues relating to intra-tumoural heterogeneity are at the forefront of 
contemporary molecular pathology. One concerns the degree to which a single core-cut 
biopsy can represent a biomarker’s expression across the tumour. We assessed this 
using a genome-wide approach. We also determined whether two common clinical 
practices around the time of surgery significantly affected the expression of particular 
genes or activation of certain pathways. Systematic changes resulting from either 
process would be relevant to any studies of excised breast cancer, since virtually all 
excisions occur after diagnostic core-cut and many will involve x-ray of the tumour 
before its fixation/stabilisation. Data from other studies may differ due to differences 
between the analytical platforms used. 
The variability in whole genome expression data between tissue samples taken peri-
surgically has been studied in only small tumour sets (greatest number 13, discussed 
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below)[4-7]. Pure study of intra-tumoural heterogeneity is best conducted by taking 
multiple samples from a tumour at the same time. However, the systematic changes 
occurring in our studies were very modest and will have had little to no perceptible 
impact on the overall correlations observed. The range of correlations was similar across 
both studies and overall provided data on 79 tumours. The poorest of the correlations 
was 0.86 with the large majority being above 0.95 and several being >0.99. Thus gene 
expression overall shows only modest variability across tumours. 
Most investigators are more interested in the variation in expression across the tumour 
for their gene or genes of interest. Our on-line data [10] will allow them to evaluate that. 
For illustration we chose 18 genes frequently studied in breast cancer. In general the 
correlation of the individual genes between the samples was higher for those genes with 
wide ranges, e.g. TFF1 (6-log2 range) and ERBB2 (5-log2 range) than those with narrow 
ranges, e.g. SNAI2 (1.5-log2 range) and MKI67 (<1.0-log2 range). The correlations 
between individual genes were all worse than those for the genome-wide analyses where 
there was an approximately 8-log2 range of expression. 
We have previously reported that the 60-minute delay in fixation in Study I had no 
significant impact on immunohistochemical expression of ER, PgR, Ki67, HER2, pAKT or 
pERK1/2 [2]. Similarly, no genes were found to differ at an FDR<0.05. However, several 
genes related to stress (e.g. DUSP1) and/or known as early response genes (eg RGS1, 
RGS2, and FOSB) were among those most highly ranked according to change. In Study 
II, where the larger number of samples provided greater statistical power, the same 
genes (e.g. RGS1, FOSB and DUSP1) or similar genes (e.g. FOS) ranked in the top 10 
genes with changed expression. This suggests that the changes in these early response 
and stress pathways were true findings in both studies. It is important to note for Study 
II that no record was made in POETIC of whether excised tumours were subject to x-ray 
before taking of RNAlater-stored core-cuts. At the Royal Marsden all impalpable tumours 
and most tumours resected via wide-excision (totalling about 50% of operations) are x-
rayed. We have informally determined that similar approaches are in place across the 
UK. Some of the similarities in the genes changing between the studies may therefore 
have been due to a proportion of the tumours in Study II being subjected to x-ray before 
stabilisation. It should be noted however that while the similarities in the gene changes 
between the two studies are consistent with delays due to X-ray being responsible in 
study II there are multiple other factors that occur around surgery that could also 
contribute. These include the time taken for a sample to reach histopathology where 
some centres may have taken cores for the POETIC study and delays due to sentinel 
node biopsy which may have occurred prior to the core being taken. Nonetheless the 
changes observed in Study II are likely to represent those that occur between diagnostic 
and surgical samples in common practise and will affect the measurement/study of early 
response genes in excised tumours. 
Two smaller studies have assessed the impact of delay to fixation on global gene 
expression [4, 5]. In the Borgan study, changes in FOSB and JUND, while perceptible 
after 60 minutes, were much greater after 3 hours. The correlation of these changes 
with time since tumour removal make it likely that they are due to stress of tissue 
cutting and/or its exposure changed oxygen tension as opposed to the impact of other 
procedures around surgery such as anaesthesia. The pathway and network analyses 
undertaken with Study I revealed changes in oxidative phosphorylation and 
mitochondrial dysfunction. This is also consistent with the exposure of the core-cuts to 
changed oxygen tension or ischemia. The correlation of mitochondrial dysfunction also 
correlated quantitatively with time between core-cut taking and fixation supports this 
change being causatively associated. 
Despite the lack of change in the pre-specified immune signatures IL6 expression 
increased in both studies and was among the genes identified by Jeselsohn in a similar 
but smaller study. The change in IL6 levels in Study II was sufficiently heterogeneous 
between tumours to nullify the highly significant correlation between the A and B 
samples in Study I, suggesting that the IL6 changes were more related to the effects of 
the initial biopsy than to the short delays around surgery. IL6 is a pleiotropic cytokine 
secreted by T-cells and macrophages in both systemic and localised immune activation. 
Its role in breast cancer has been reviewed by Dethlefsen and colleagues [14]. Changes 
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in IGFBP2 and particularly MYC in Study II also confirmed those seen in the Jeselsohn 
study, but there was little support for the other 10 genes identified as significant in that 
study. Like IL6 these two genes are widely studied in breast cancer. Interpretation of 
data on them must take account of the effects of diagnostic biopsies. 
Some smaller genome–wide analyses between paired biopsies either side of surgery 
have been reported. Riis et al [7] studied 13 patients with the time between diagnostic 
and surgical samples ranging between 2 and 8 weeks. As in the current study genes 
related to early response, including FOSB and to oxidative stress including DUSP1 were 
differentially expressed between the 2 samples. Similar increases in early response 
genes including FOS were also reported in 16 patients in which fine needle aspirates 
were taken presurgically and immediately after tumour excision but the time between 
samples was not stated [8]. Neither of these small studies, identified IL6, IGFB2 or MYC 
as a changing gene but may have been due to their low statistical power. 
There were no systematic differences in categorisation of the tumours into the intrinsic 
subgroups in either study but discordance was noted between the luminal A versus B 
subtypes, even after quality control of the RNA and removing technical platform bias 
with normalization and standardization of expression profiles. In Study II, 15 to 20% of 
tumours considered luminal A on one core-cut were typed as luminal B or normal-like on 
the other. Allocation of subtypes is made according to the highest correlation coefficient 
with the archetypical centroid for each subtype irrespective of the proximity of the 
correlations to the subtypes although an early report [15] described 43/115 (37%) of 
tumours as having a low correlation to any of the subtypes. Not surprisingly, we found 
that subtype discordances were largely associated with small differences between 
correlations with luminal A and luminal B centroids. The level of discordance in subtyping 
is important to appreciate given the prominence of intrinsic subtyping in clinical studies 
of breast cancer and its use for determining whether to allocate chemotherapy [16]. 
 
Conclusions 
These studies of both random and systematic variability of global gene expression in the 
context of presurgical study of breast cancer have revealed modest differences in most 
genes/pathways but confirmed substantial changes in the expression of early response 
genes that appear to be due to ischemia after surgery and in IL6, IGFB2 and MYC that 
appear to be responses to initial core-cut biopsy. The data are relevant to all studies of 
breast cancer since excised tumours almost always have been preceded by core-cut. We 
provide a reference source [10] for others to assess the potential impact variability in 
the study of their own genes of interest. 
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Figure legends 
Figure 1. Hierarchical clustering with Euclidean distance and average linkage, 
based on (A) Study I.  Clustering of 24,395 probes and 23 pairs of samples; B) 
Study II. Clustering of 32,332 probes and 56 pairs of samples. In brief, probes 
and samples were grouped based on similarities calculated using the Euclidean distance 
method and average linkage (Additional file 1. Supplementary information). Sample 
dendrogram bars were coloured according to PAM50 intrinsic subtypes and Pairing of 
samples respectively. PAM50 color: green = Normal; dark blue = LumA; light blue = 
LumB; purple = Her2-enriched; red = Basal; grey = Paired together: light green = 
Unpaired first sample; dark green = Unpaired second sample. 
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Figure 2. Line Diagram of the paired IL6 expression levels in Study I and Study 
II. Study I IL6 expression levels of samples A and B and Study II IL6 expression levels 
at diagnosis (D) and surgery (S). Marked in red are samples with >50% increase in 
expression. 
 
Tables 
Table 1. Correlation of paired expression levels in 5 genes reported in breast 
cancer (complete list of 18 genes in Table S2) and 9 genes identified by 
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Table 2. Top 8 genes significantly different in paired samples of Study I and 
Study II 
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Table 1. Correlation of paired expression levels in 5 genes reported in breast cancer and 9 genes identified by Jeselsohn. 
 
  STUDY I STUDY II  STUDY I vs. STUDY II 
  Gene symbol R P value 
Geometric 
Mean of 
B/A 
95% CI 
 
R P value 
Geometric 
Mean of 
S/D 
95% CI 
 
Z-value P-value (2 tail) 
 
BAG1 0.713 0.0001 0.971 0.946-0.996 0.734 <0.0001 1.043 0.984-1.106 -0.17 0.865 
MKi67 0.354 0.0978 1.009 0.962-1.058 0.522 <0.0001 0.977 0.930-1.027 -0.8 0.4237 
MAPT 0.847 <0.0001 0.806 0.692-0.938 0.811 <0.0001 1.108 0.965-1.273 0.44 0.6599 
PGR 0.522 0.0106 1.093 0.946-1.263 0.824 <0.0001 0.978 0.894-1.070 -2.25 0.0244 
SNAI2 0.430 0.0408 0.897 0.790-1.018 0.481 0.0002 0.940 0.838-1.054 -0.25 0.8026 
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13
) 
(a
) 
im
m
un
e 
re
la
te
d IGFBP2 0.583 0.0035 1.051 0.862-1.282 0.784 <0.0001 1.136 1.031-1.251 -1.48 0.1389 
IL6 0.712 0.0001 1.108 1.003-1.223 0.194 0.1525 1.167 1.079-1.262 2.65 0.008 
CD68 0.412 0.0509 1.065 0.889-1.272 0.464 0.0003 1.099 0.985-1.226 -0.25 0.8026 
CD14 0.553 0.0062 1.047 0.905-1.211 0.355 0.0074 1.017 0.901-1.148 0.96 0.3371 
CD52 0.755 < 0.0001 1.085 0.923-1.276 0.436 0.0008 1.038 0.876-1.230 1.97 0.0488 
CD44 0.458 0.0278 0.927 0.788-1.091 0.816 <0.0001 0.952 0.890-1.019 -2.48 0.0131 
PPARG 0.315 0.1438 0.806 0.608-1.068 0.343 0.0096 0.993 0.870-1.132 -0.12 0.9045 
ADM 0.476 0.0217 0.931 0.720-1.204 0.544 <0.0001 1.122 0.964-1.306 -0.35 0.7263 
VEGFA 0.653 0.0007 1.043 0.967-1.124 0.647 <0.0001 0.991 0.930-1.055 0.04 0.9681 
(b
) 
no
n-
im
m
un
e 
re
la
te
d 
CENPF 0.781 < 0.0001 1.039 0.913-1.183 0.729 <0.0001 1.062 0.959-1.176 0.46 0.6455 
MYC 0.509 0.0132 1.076 0.897-1.292 0.65 <0.0001 1.439 1.241-1.668 -0.82 0.4122 
CCNB1 0.413 0.0501 0.976 0.883-1.078 0.469 0.0003 1.010 0.919-1.107 -0.27 0.7872 
MAP1LC3B 0.598 0.0026 0.957 0.882-1.038 0.809 <0.0001 0.971 0.933-1.010 -1.65 0.099 
SNAI1 ND ND ND ND ND ND ND ND ND ND 
ND=non-Detected 
 
  
Table 2. Top 8 genes significantly different in paired samples of Study I and Study II 
STUDY I  STUDY II 
Accession Symbol Parametric p-value FDR FC  Accession Symbol 
Parametric 
p-value FDR FC 
NM_006732 FOSB 0.0014 0.138 2.08  NM_005252 FOS < 1e-07 < 1e-07 4.00 
NM_004417 DUSP1 0.0003 0.133 1.72  NM_002922 RGS1 < 1e-07 < 1e-07 3.23 
NM_002923 RGS2 0.0003 0.133 1.59  NM_004417 DUSP1 < 1e-07 < 1e-07 3.13 
NM_003407 ZFP36 0.0005 0.133 1.54  NM_000517 HBA2 < 1e-05 0.003 -2.90 
NM_033027 AXUD1 0.0001 0.087 1.49  NM_000518 HBB < 1e-05 0.006 -2.83 
NM_004566 PFKFB3 0.0030 0.153 -1.48  NM_000517 HBA2 < 1e-05 0.007 -2.64 
NM_018955 UBB 0.0037 0.155 -1.46  NM_000558 HBA1 < 1e-04 0.008 -2.39 
NM_005063 SCD 0.0003 0.133 -1.45  NM_006732 FOSB < 1e-06 0.001 2.38 
 
 
 
Additional file 1. Supplementary Information 
Gene expression analysis and data pre-processing 
Total RNA was extracted using miRNeasy (Qiagen, Sussex, UK). RNA quality was 
checked using an Agilent Bioanalyser (Santa Clara, CA, USA): samples with RNA 
integrity values of <4 were excluded from further analysis. RNA amplification, la-
belling and hybridization on HumanHT-12_V3 (study I samples) and HumanHT-
12_V4 (study II samples) expression BeadChips (Illumina, San Diego, CA, USA) 
were performed according to the manufacturer's instructions. Illumina raw data 
was extracted using GenomeStudio software and was transformed and normal-
ized using variance-stabilizing transformation, robust spline normalization method 
included in the R package (lumi) (http://www.bioconductor.org). The data was 
then batch-corrected using the function (ComBat) in the R package (sva). Paired 
samples were excluded from further analysis if their fraction of detected genes 
was <30% and identified as outliers by a sample outlier detection function in the 
lumi package. Probes were filtered out if they were not detected in any of the 
samples (detection p>0.01). Gene expression data from this study is deposited at 
GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73237) with ac-
cession number GSE73237. 
 
Gene Signatures 
Entrez Gene ID was used as gene identifier in gene signatures. The HumanHT-
12_V4_0_R2_15002873_B annotation file was used to map the EntrezGeneIDs to 
the corresponding Illumina probe IDs. Gene signature scores were weighted 
averages as described previously [1]. 
We evaluated three candidate gene sets: i) metagene wound healing signature 
[2]; ii) immune response metagene [3] and iii) 13 of the 14 genes identified as 
changing in the Jeselsohn study [4] (SNAI1 was not detected on the Illumina 
platform). We also studied the effects on 18 pre-specified genes that we selected 
as being particularly relevant to breast cancer from prior studies.   
Each tumour sample was classified into one of the five intrinsic subtypes based on 
the PAM50 classifier [5]. Prior to classification, technical bias between these data 
and the training data were minimized to ensure accurate calls across 
heterogeneous platforms. Under the assumption that The Cancer Genome Atlas 
ER+ cohort and the baseline specimens of the POETIC cohort were similar, gene-
wise differences in the mean and variance of these two groups represent 
technical bias. These differences were removed from the POETIC and study I 
cohorts prior to PAM50 classification respectively.  
 
Single sample intrinsic subtype prediction was performed by calculating a 
Spearman rank correlation coefficient between the 50-gene expression values of 
an individual sample compared to each of the average gene expression (centroid) 
values for Luminal A, Luminal B, HER2-Enriched, Basal-like, and Normal. The 
subtype classification for the study sample is assigned to the centroid with the 
highest correlation.  
 
Data analysis and Statistical Methods 
Pearson correlation coefficient was used to assess the association of the: i) 
detectable probes between the paired samples and ii) pre-selected genes 
between paired samples' expression levels. Univariate paired or unpaired T-tests 
together with multivariate permutation tests were used to identify differentially 
expressed genes between the paired samples. The significantly differentially 
expressed genes were subjected to Ingenuity Pathway Analysis (IPA). Pathways 
were considered as significantly altered if p<0.05 after using Benjamini-Hochberg 
Multiple Testing Correction. Wilcoxon matched-pairs signed rank test was used to 
evaluate the significance of the percentage increase of expression between pairs. 
The correlation of the difference in gene expression between biopsies and the 
length of the time interval between the biopsies was evaluated using Spearman 
rank correlation. The significance of the difference between 2 correlation 
coefficients obtained in study I and study II respectively was calculated using the 
Fisher r-to-z transformation [6] using the online calculator 
(http://vassarstats.net/rdiff.html).  For each sample we calculated the following: 
(a) numeric difference of the LumA and LumB centroid correlation coefficients 
(i.e. LumA correlation coefficient minus Lum B correlation coefficient) and (b) 
numeric difference of their LumB and HER2-enriched correlation coefficients (i.e. 
LumB correlation coefficient minus HER2-enriched subtype correlation 
coefficient). Medians of these centroid correlation coefficients were reported and 
approximate 95% C.I. intervals were calculated using the adjusted bootstrap 
percentile method where appropriate [7]. No formal statistics comparison of the 
medians is performed. 
GraphPad Prism 6 (Graphpad Software Inc.) was used for some of the statistical 
analyses in this study. 
 
Hierarchical clustering method 
To identify the clusters in gene expression between samples we used the 
Euclidean distance method and average linkage of sampleRelation function within 
the “lumi” R-package. The samples were then color annotated according to their 
PAM50 intrinsic subtypes (green = Normal; dark blue = LumA; light blue = 
LumB; purple = Her2-enriched; red = Basal) and whether or not the paired 
samples were clustered together (grey = Paired together: light green = Unpaired 
first sample; dark green = Unpaired second sample). In the final heatmaps of 
gene expression for the probes, they were generated based on the same 
clustering method (i.e. Euclidean distance method and average linkage), but 
keeping the order of samples. Function named colorRampPalette within R-
package was used to specify the gradient of the colors. 
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Figure S4 
A. Study I 
B. Study II 
Figure S5 
Study II Figure S6 
Table S1. Demographics for Study I and Study II
n % n %
Age at randomisation (years)
50-59 12 52.2 4 7.1
60-69 5 45.5 16 28.6
70-79 2 3.3 16 28.6
≥80 4 6.8 20 35.7
Age at randomisation - Median (IQR) 55 (47-70) 76.6 (67.4 - 81.7)
Tumour grade
G1 6 26.1 8 14.3
G2 8 34.8 30 53.6
G3 8 34.8 8 14.3
Not known 1 4.3 10 17.9
Tumour size (cm)
≤2 5 21.7 14 25
>2 & ≤5 14 60.9 41 73.2
>5 4 17.4 1 1.8
Nodal status
Negative 14 60.9 33 58.9
Positive 8 34.8 23 41.1
Not known 1 4.3
Histological type
Ductal 18 78.3 43 76.8
Lobular 3 13.0 9 16.1
DCIS 2 8.7
Mucinous 3 5.4
Mixed ductal and lobular 1 1.8
ER status
Positive 21 91.3 56 100
Negative 2 8.7
PgR status
Positive 19 82.6 44 78.6
Negative 4 17.4 6 10.7
Not known 6 10.7
HER2 status
Negative 20 87.0 46 82.1
Positive 3 13.0 8 14.3
Not known 2 3.6
Ki67 (%) at baseline - Median (IQR)* 14.2 6.9-17.1 19 11.9 - 33.6
*Baseline Ki67 data unavailable for 5/56 patients
Study IIStudy I
Nodal status and HER status are recorded post-surgery, all other characteristics 
recorded pre-surgery. Tumour size is measured either by ultrasound or clinical 
examination
Table S2. Correlation of paired expression levels in 18 genes reported in breast cancer and    
Gene 
symbol R P value
Geometric 
Mean of 
B/A
95% CI R
AURKA 0.677 0.0004 0.951 0.796-1.137 0.759
BAG1 0.713 0.0001 0.971 0.946-0.996 0.734
CCND1 0.621 0.0016 1.133 0.912-1.408 0.645
ERBB2 0.811 <0.0001 0.926 0.786-1.091 0.844
ESR1 0.847 <0.0001 0.958 0.787-1.165 0.715
FOXA1 0.686 0.0003 0.922 0.796-1.067 0.597
GATA3 0.756 <0.0001 1.018 0.847-1.223 0.704
GPR160 0.805 <0.0001 1.118 0.975-1.282 0.554
MKi67 0.354 0.0978 1.009 0.962-1.058 0.522
MAPT 0.847 <0.0001 0.806 0.692-0.938 0.811
MLPH 0.741 <0.0001 1.06 0.901-1.246 0.741
NAT1 0.604 0.0023 0.813 0.626-1.056 0.717
PGR 0.522 0.0106 1.093 0.946-1.263 0.824
SCUBE2 0.806 <0.0001 1.158 0.923-1.453 0.857
SLAMF8 0.621 0.0016 0.996 0.909-1.090 0.655
SNAI2 0.43 0.0408 0.897 0.790-1.018 0.481
TFF1 0.932 <0.0001 1.148 0.932-1.413 0.842
TOP2A 0.682 0.0003 0.977 0.766-1.247 0.651
IGFBP2 0.583 0.0035 1.051 0.862-1.282 0.784
IL6 0.712 0.0001 1.108 1.003-1.223 0.194
CD68 0.412 0.0509 1.065 0.889-1.272 0.464
CD14 0.553 0.0062 1.047 0.905-1.211 0.355
CD52 0.755 < 0.0001 1.085 0.923-1.276 0.436
CD44 0.458 0.0278 0.927 0.788-1.091 0.816
PPARG 0.315 0.1438 0.806 0.608-1.068 0.343
ADM 0.476 0.0217 0.931 0.720-1.204 0.544
VEGFA 0.653 0.0007 1.043 0.967-1.124 0.647
CENPF 0.781 < 0.0001 1.039 0.913-1.183 0.729
MYC 0.509 0.0132 1.076 0.897-1.292 0.65
CCNB1 0.413 0.0501 0.976 0.883-1.078 0.469
MAP1LC3B 0.598 0.0026 0.957 0.882-1.038 0.809
SNAI1 ND ND ND ND ND
STUDY I  
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              d 9 identified by Jeselsohn.
P value
Geometric 
Mean of 
S/D
95% CI Z-value P-value (2 tail)
<0.0001 1.01 0.923-1.106 -0.65 0.5157
<0.0001 1.043 0.984-1.106 -0.17 0.865
<0.0001 1.048 0.920-1.194 -0.15 0.8808
<0.0001 1.065 0.973-1.166 -0.4 0.6892
<0.0001 1.027 0.910-1.159 1.33 0.1835
<0.0001 1.037 0.952-1.129 0.58 0.5619
<0.0001 1.083 0.974-1.203 0.43 0.6672
<0.0001 1.034 0.923-1.159 1.86 0.0629
<0.0001 0.977 0.930-1.027 -0.8 0.4237
<0.0001 1.108 0.965-1.273 0.44 0.6599
<0.0001 1.107 0.992-1.235 0 1
<0.0001 0.944 0.750-1.188 -0.77 0.4413
<0.0001 0.978 0.894-1.070 -2.25 0.0244
<0.0001 0.989 0.846-1.156 -0.63 0.5287
<0.0001 1.027 0.935-1.129 -0.22 0.8259
0.0002 0.94 0.838-1.054 -0.25 0.8026
<0.0001 1.216 0.980-1.509 1.7 0.0891
<0.0001 1.089 0.944-1.255 0.21 0.8337
<0.0001 1.136 1.031-1.251 -1.48 0.1389
0.1525 1.167 1.079-1.262 2.65 0.008
0.0003 1.099 0.985-1.226 -0.25 0.8026
0.0074 1.017 0.901-1.148 0.96 0.3371
0.0008 1.038 0.876-1.230 1.97 0.0488
<0.0001 0.952 0.890-1.019 -2.48 0.0131
0.0096 0.993 0.870-1.132 -0.12 0.9045
<0.0001 1.122 0.964-1.306 -0.35 0.7263
<0.0001 0.991 0.930-1.055 0.04 0.9681
<0.0001 1.062 0.959-1.176 0.46 0.6455
<0.0001 1.439 1.241-1.668 -0.82 0.4122
0.0003 1.01 0.919-1.107 -0.27 0.7872
<0.0001 0.971 0.933-1.010 -1.65 0.099
ND ND ND ND ND
STUDY II STUDY I vs. STUDY II
Table S3. A) Canonical pathways and B) Top networks    
Table S3A
Canonical Pathways B-H p-value
Oxidative Phosphorylation 8.9125E-05
Mitochondrial Dysfunction 0.00083176
CDK5 Signaling 0.01479108
Oleate Biosynthesis II (Animals) 0.01659587
Protein Ubiquitination Pathway 0.03801894
Aldosterone Signaling in Epithelial Cells 0.03801894
Table S3B
ID Score
1 39
2 31
3 28
4 21
5 8
6 2
         identified in Study I.
Molecules
CYB5A,ATP5O,ATP5F1,ATP5J,ATP5C1,COX5B
CYB5A,ATP5O,ATP5F1,ATP5J,ATP5C1,COX5B
GNAS,LAMB1,FOSB,PPP1R1B
CYB5A,SCD
UBB,PSMA3,PSMC6,HSP90AA1,HSPE1
DUSP1,SGK1,HSP90AA1,HSPE1
Focus Molecules Top Diseases and Functions
18
DNA Replication, 
Recombination, and Repair, 
Nucleic Acid Metabolism, 
Small Molecule Biochemistry
15
DNA Replication, 
Recombination, and Repair, 
Energy Production, Nucleic 
Acid Metabolism
14
Developmental Disorder, 
Hereditary Disorder, 
Metabolic Disease
11
Cell Death and Survival, 
Embryonic Development, 
Cellular Movement
5
Cell Signaling, Molecular 
Transport, Nucleic Acid 
Metabolism
1
Cancer, Organismal Injury 
and Abnormalities, 
Reproductive System 
Disease
Molecules in Network
20s proteasome,26s Proteasome,ADCY,BST2,Calcineurin 
protein(s),Cg,Creb,DUSP1,ERK1/2,FOSB,FSH,GNAS,hemoglobin,HSPE1,Insulin,KLF13,Lh,M
AP2K1/2,NR4A2,Pde,PDE5A,PDGF BB,PDXK,PFKFB3,phosphatase,Pkg,PPP1R1B,PRDX2,Pro-
inflammatory Cytokine,PSMC6,PTPLB,RETSAT,RGS2,ZAK,ZFP36
adenosine-tetraphosphatase,AGPAT2,ARRB1,ARRDC1,ATP 
synthase,ATP5C1,ATP5D,ATP5F1,ATP5H,ATP5I,ATP5J,ATP5O,ATP5S,ATPase,caspase,CCT8,
Ck2,F0 ATP synthase,F1 ATPase,FOXRED1,GTPase,HSP90AA1,HSPCA,IARS2,MT-
ATP6,Pkc(s),PSMA3,PTCH2,RGS1,RGS11,RNA polymerase II,TPI1,UBB,XAF1,ZNF74
AKIRIN2,ARL17A/ARL17B,C19orf66,C6orf62,CCDC117,CHPT1,CNFN,CSRNP1,EIF4H,ELAVL1,
EML4,ETFA,ETFDH,FAM83F,GSTO2,HIGD1A,HNF4A,IER3IP1,KBTBD4,KIAA0247,KLHL6,LGAL
SL,LIPT1,MRPL57,NSA2,PAQR7,RAB2B,RPL36AL,SLC35A5,STT3A,SZRD1,TMEM68,UBC,UGP
2,ZNF106
Akt,Ap1,CD3,COX5B,CYB5A,cytochrome-c oxidase,ERK,estrogen receptor,ETS1,Focal 
adhesion kinase,Growth hormone,Histone h3,Hsp70,IgG,IL1,IL12 
(complex),Immunoglobulin,Integrin,ITGAV,Jnk,LAMB1,LDL,Mapk,MME,NFkB 
(complex),NRP1,P38 MAPK,PI3K (complex),Pka,PPIAL4G (includes others),SCD,SGK1,Tgf 
beta,TSPAN3,Vegf
ADCY9,AP5Z1,APP,CCNB1IP1,CHRM4,CRHR2,DENND6B,DNAJC5,DRD2,FAM213A,FOXK1,F
OXK2,FYCO1,FZD5,GNB3,GNRHR,GPR3,HCFC2,HTR2A,IRF2BP1,IRF2BP2,IRF2BPL,K 
Channel,Na+,K+ -ATPase,Na-k-
atpase,PAWR,PDXP,PPAP2B,PPP1R1B,PPP3CA,PRDX5,PTGDR,RGS1,SSTR2,voltage-gated 
calcium channel
NUFIP1,SNORD13
Table S4. Genes correlated with time elapsed in Study I. 
Symbol Probe ID Rho P value D.F. Adjusted P value
HTRA3 ILMN_1812669 0.758 0.00003 23 0.443
FGFRL1 ILMN_1795865 0.744 0.00005 23 0.443
AGPAT2 ILMN_1732176 0.725 0.00009 23 0.443
TP53I3 ILMN_2358919 0.723 0.00010 23 0.443
PSMB10 ILMN_1683026 0.720 0.00011 23 0.443
RRAGD ILMN_1699772 0.715 0.00013 23 0.443
G0S2 ILMN_1691846 0.712 0.00014 23 0.443
MYL6 ILMN_2326071 0.707 0.00016 23 0.443
CEBPA ILMN_1715715 0.707 0.00016 23 0.443
PC ILMN_1671489 0.695 0.00023 23 0.509
FLJ20254 ILMN_1716907 0.692 0.00026 23 0.509
LGALS1 ILMN_1723978 0.687 0.00030 23 0.509
ADAMTS7 ILMN_2211790 0.683 0.00033 23 0.509
ECHS1 ILMN_1718132 0.683 0.00033 23 0.509
COL5A3 ILMN_1796288 0.681 0.00035 23 0.509
GPX4 ILMN_2378952 0.680 0.00036 23 0.509
DULLARD ILMN_2133638 0.678 0.00038 23 0.509
PEX19 ILMN_1658759 0.675 0.00041 23 0.509
LETM1 ILMN_1710668 0.673 0.00043 23 0.509
LOC441956 ILMN_1719826 0.673 0.00043 23 0.509
GLYCTK ILMN_1791222 0.673 0.00044 23 0.509
GLUL ILMN_1653496 0.669 0.00049 23 0.538
BCR ILMN_1670398 0.667 0.00051 23 0.538
PKD1L2 ILMN_2372316 0.665 0.00054 23 0.544
NMB ILMN_2347592 0.662 0.00058 23 0.565
SMPD1 ILMN_1757370 0.656 0.00068 23 0.587
BAI2 ILMN_1773109 0.653 0.00074 23 0.587
SETDB1 ILMN_1718207 0.652 0.00075 23 0.587
MAPK10 ILMN_2340131 0.645 0.00089 23 0.587
ACP6 ILMN_2234343 0.644 0.00091 23 0.587
OSTM1 ILMN_1720303 0.644 0.00092 23 0.587
INPP4A ILMN_1652647 0.643 0.00094 23 0.587
NOL3 ILMN_2059797 0.643 0.00094 23 0.587
FBXO16 ILMN_1715823 0.640 0.00101 23 0.587
PGM1 ILMN_1800659 0.639 0.00103 23 0.587
CABLES1 ILMN_1653001 0.638 0.00104 23 0.587
FAM90A1 ILMN_1696684 0.636 0.00109 23 0.587
KIAA0182 ILMN_1807767 0.636 0.00109 23 0.587
NCSTN ILMN_1735180 0.636 0.00111 23 0.587
LOC642946 ILMN_1782178 0.634 0.00116 23 0.587
FAM89A ILMN_1712859 0.633 0.00117 23 0.587
CNIH3 ILMN_1749071 0.632 0.00120 23 0.587
ICA1 ILMN_1814787 0.632 0.00120 23 0.587
PC ILMN_2340347 0.632 0.00120 23 0.587
NUTF2 ILMN_1655046 0.630 0.00128 23 0.587
ADAMTS14 ILMN_2358134 0.626 0.00138 23 0.609
PHKG1 ILMN_2113102 0.625 0.00142 23 0.609
AGPAT2 ILMN_1681081 0.624 0.00145 23 0.609
HP1BP3 ILMN_1701169 0.623 0.00150 23 0.619
EPGN ILMN_1815313 0.618 0.00168 23 0.651
BTD ILMN_1699728 0.617 0.00172 23 0.651
MYO1C ILMN_2329165 0.617 0.00172 23 0.651
ZNF423 ILMN_1763602 0.617 0.00172 23 0.651
BMP1 ILMN_1800412 0.612 0.00192 23 0.708
AADAC ILMN_1760414 0.610 0.00200 23 0.715
DHX9 ILMN_1676285 0.610 0.00200 23 0.715
MSRA ILMN_2228180 0.609 0.00202 23 0.715
MED10 ILMN_1707631 0.608 0.00207 23 0.721
TNFRSF21 ILMN_1699695 0.604 0.00228 23 0.761
MPV17 ILMN_1691090 0.601 0.00243 23 0.786
POMC ILMN_2403664 0.600 0.00245 23 0.786
MAPK10 ILMN_1748281 0.600 0.00248 23 0.786
BCL2L13 ILMN_2181445 0.599 0.00253 23 0.792
LGI2 ILMN_1767900 0.595 0.00273 23 0.831
NDUFV2 ILMN_2086417 0.595 0.00273 23 0.831
SLC22A18AS ILMN_1691048 0.594 0.00281 23 0.837
AQP7 ILMN_1738494 0.591 0.00296 23 0.838
CIDEA ILMN_2390318 0.591 0.00299 23 0.838
PGA5 ILMN_1717572 0.591 0.00299 23 0.838
MKNK1 ILMN_1750429 0.588 0.00318 23 0.862
CST6 ILMN_1698666 0.587 0.00325 23 0.869
MMP9 ILMN_1796316 0.586 0.00328 23 0.869
SCD ILMN_1689329 0.583 0.00348 23 0.913
ACADVL ILMN_2263466 0.581 0.00362 23 0.913
ENO1 ILMN_1710756 0.581 0.00362 23 0.913
FBXL8 ILMN_1682037 0.579 0.00377 23 0.913
APOF ILMN_1809311 0.577 0.00392 23 0.913
GSS ILMN_1683462 0.575 0.00412 23 0.913
FCGR2A ILMN_1706523 0.574 0.00416 23 0.913
KDELR3 ILMN_1798952 0.574 0.00416 23 0.913
RER1 ILMN_1812067 0.574 0.00416 23 0.913
LOC441150 ILMN_1743755 0.573 0.00424 23 0.913
F2RL1 ILMN_1673113 0.573 0.00428 23 0.913
FBLN2 ILMN_1721769 0.573 0.00428 23 0.913
LOC647520 ILMN_1767546 0.573 0.00428 23 0.913
VMO1 ILMN_1735910 0.572 0.00437 23 0.913
WDR79 ILMN_1693669 0.571 0.00441 23 0.913
INF2 ILMN_1727248 0.571 0.00445 23 0.913
LACTB ILMN_1693830 0.570 0.00449 23 0.913
COPA ILMN_1811615 0.569 0.00462 23 0.913
LOC653604 ILMN_1793461 0.569 0.00462 23 0.913
UBTD1 ILMN_1794914 0.569 0.00462 23 0.913
GPR64 ILMN_2349071 0.567 0.00476 23 0.913
C1ORF86 ILMN_2097790 0.567 0.00480 23 0.913
IGF1 ILMN_1709613 0.567 0.00480 23 0.913
SPI1 ILMN_2392043 0.566 0.00485 23 0.913
COL1A1 ILMN_1701308 0.566 0.00490 23 0.913
PCOLCE2 ILMN_1746888 0.566 0.00490 23 0.913
SDHB ILMN_1667257 0.566 0.00490 23 0.913
DBNL ILMN_2376289 0.565 0.00499 23 0.913
EPM2AIP1 ILMN_1682658 -0.566 0.00490 23 0.913
TMEM178 ILMN_1678403 -0.569 0.00462 23 0.913
TUBB4 ILMN_1682459 -0.571 0.00445 23 0.913
RANBP6 ILMN_1780842 -0.571 0.00441 23 0.913
C3ORF63 ILMN_1661409 -0.572 0.00437 23 0.913
LOC153364 ILMN_1769449 -0.578 0.00385 23 0.913
NOL5A ILMN_1705407 -0.579 0.00377 23 0.913
LOC391347 ILMN_1654185 -0.588 0.00318 23 0.862
HSPA2 ILMN_1766499 -0.590 0.00302 23 0.838
LRBA ILMN_1652160 -0.591 0.00299 23 0.838
LOC285053 ILMN_1660832 -0.592 0.00290 23 0.838
LOC374443 ILMN_1708905 -0.594 0.00281 23 0.837
CXCL2 ILMN_1682636 -0.602 0.00235 23 0.776
GOLSYN ILMN_1738989 -0.605 0.00223 23 0.756
SGK3 ILMN_1747020 -0.606 0.00218 23 0.750
HS.562504 ILMN_1874323 -0.616 0.00173 23 0.651
TWSG1 ILMN_1726967 -0.621 0.00155 23 0.630
LOC647009 ILMN_1739045 -0.624 0.00145 23 0.609
LOC136143 ILMN_1668228 -0.627 0.00137 23 0.609
LOC439949 ILMN_1893633 -0.630 0.00128 23 0.587
HS.545232 ILMN_1875380 -0.631 0.00123 23 0.587
LOC643171 ILMN_1748666 -0.632 0.00122 23 0.587
LOC651453 ILMN_1709948 -0.632 0.00120 23 0.587
FLJ11151 ILMN_1662865 -0.633 0.00117 23 0.587
RND3 ILMN_1759513 -0.640 0.00101 23 0.587
HS.569566 ILMN_1838942 -0.651 0.00078 23 0.587
SMARCA1 ILMN_2376258 -0.654 0.00071 23 0.587
Table S5. Top pathways identified from 116 genes correlated with time elapsed.
Ingenuity Canonical Pathways p-value
Adipogenesis pathway 0.0009
Mitochondrial Dysfunction 0.0022
Atherosclerosis Signaling 0.0058
Glutamine Biosynthesis I 0.0060
LXR/RXR Activation 0.0060
Hepatic Fibrosis / Hepatic Stellate Cell Activation 0.0066
BMP signaling pathway 0.0100
Intrinsic Prothrombin Activation Pathway 0.0123
Axonal Guidance Signaling 0.0145
Inhibition of Angiogenesis by TSP1 0.0158
Dendritic Cell Maturation 0.0162
Glutathione Biosynthesis 0.0178
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 0.0229
ILK Signaling 0.0234
Biotin-carboxyl Carrier Protein Assembly 0.0240
UVC-Induced MAPK Signaling 0.0263
Gα12/13 Signaling 0.0324
GDP-glucose Biosynthesis 0.0355
RhoA Signaling 0.0355
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 0.0398
Unfolded protein response 0.0407
Glucose and Glucose-1-phosphate Degradation 0.0417
Cardiac Hypertrophy Signaling 0.0427
IL-12 Signaling and Production in Macrophages 0.0447
Glioma Invasiveness Signaling 0.0457
Airway Pathology in Chronic Obstructive Pulmonary Disease 0.0468
Sphingomyelin Metabolism 0.0468
Myc Mediated Apoptosis Signaling 0.0479
Molecules
AGPAT2,ZNF423,CEBPA,SETDB1,FGFRL1
SDHB,NCSTN,GPX4,MAPK10,NDUFV2
MMP9,COL5A3,APOF,COL1A1
GLUL
MMP9,SCD,APOF,ECHS1
MYL6,MMP9,COL5A3,COL1A1,IGF1
MAPK10,BMP1,ZNF423
COL5A3,COL1A1
TUBB4A,MYL6,MMP9,BMP1,MKNK1,ADAMTS7,IGF1
MMP9,MAPK10
MAPK10,COL5A3,COL1A1,FCGR2A
GSS
MAPK10,APOF,SPI1,RND3
MYL6,MMP9,MAPK10,RND3
BTD
MAPK10,SMPD1
MYL6,F2RL1,MAPK10
PGM1
MYL6,RND3,IGF1
MAPK10,BMP1,COL1A1,IGF1
HSPA2,CEBPA
PGM1
MYL6,MAPK10,RND3,IGF1
MAPK10,APOF,SPI1
MMP9,RND3
MMP9
SMPD1
MAPK10,IGF1
Table S6. Top networks identified from 116 genes correlated with time elapsed.
ID Score Focus Molecules Top Diseases and Functions
1 34 18
Hematological System Development and 
Function, Inflammatory Response, Tissue 
Development
2 29 16
Developmental Disorder, Hereditary Disorder, 
Metabolic Disease
3 27 15
Connective Tissue Development and Function, 
Tissue Morphology, Lipid Metabolism
4 25 14
Dermatological Diseases and Conditions, 
Developmental Disorder, Hereditary Disorder
5 20 12
Organismal Injury and Abnormalities, 
Connective Tissue Disorders, Developmental 
Disorder
6 18 11
Cellular Compromise, Cellular Assembly and 
Organization, Drug Metabolism
7 18 11
Cancer, Cell-To-Cell Signaling and Interaction, 
Hematological System Development and 
Function
8 12 8
Lipid Metabolism, Molecular Transport, Small 
Molecule Biochemistry
9 2 1
Developmental Disorder, Endocrine System 
Disorders, Gastrointestinal Disease
10 2 1
Cancer, Endocrine System Disorders, 
Gastrointestinal Disease
Molecules in Network
ACADVL,Akt,AMPK,BCL2L13,BCR,CXCL2,F Actin,FCGR2A,glutathione 
peroxidase,Glycogen 
synthase,GOT,GPX4,Ifn,Ige,IgG,IgG1,Igg3,Igm,Immunoglobulin,INPP4A,Interferon 
alpha,LETM1,LGALS1,MED10,mediator,N-cor,NADPH 
oxidase,NMB,OSTM1,RND3,SCD,SPI1,TNFRSF21,TUBB4A,TWSG1
ACP6,CLDN12,COPA,ECHS1,ERGIC2,FUNDC2,GPR64,GSE1,KIAA2026,MFSD5,MPV17
,NCSTN,NDUFV2,NUP54,NUTF2,PEX3,PEX5,PEX10,PEX12,PEX13,PEX19,PEX26,PEX1
1B,PGM1,PHKG1,PXMP2,PXMP4,RER1,RRAGD,SACM1L,SLC25A17,TP53I3,UBC,UBT
D1,VASN
Actin,AGPAT2,AQP7,CD3,CEBPA,CIDEA,DHX9,ENO1,GLUL,Gsk3,Histone h3,Histone 
h4,Hsp70,Hsp90,HSPA2,Insulin,Integrin,Jnk,KDELR3,Mapk,MSRA,MYL6,MYO1C,NO
P56,P38 MAPK,PC,PI3K (complex),Pka,Pro-inflammatory 
Cytokine,Proinsulin,Rac,Ras homolog,RNA polymerase II,SETDB1,Vegf
BTD,BTG1,CPPED1,CRNKL1,CTDNEP1,CUL7,EEF2K,EPM2A,EPM2AIP1,FAM208A,FBX
L8,FBXL15,FBXO16,GAR1,GLYCTK,HIST2H3D,IFITM3,KDM2A,LPIN2,LRBA,LSM1,MAD
2L1BP,MBLAC2,NAF1,NOP10,ORC4,RANBP6,SKP1,SOD2,STK33,TMEM214,TUSC2,U
BC,WRAP53,YRDC
20s 
proteasome,ADAMTS14,Alp,Ap1,APOF,BMP1,C/ebp,COL1A1,COL5A3,collagen,Colla
gen Alpha1,Collagen type I,Collagen type II,Collagen type III,Collagen type 
V,Collagen(s),ERK1/2,FBLN2,Fgf,G0S2,gelatinase,Growth hormone,GSS,HDL-
cholesterol,IL1,IL-1R,Laminin,LDL,MMP9,PCOLCE2,PDGF 
BB,PSMB10,SMPD1,STAT5a/b,Tgf beta
Alpha catenin,Beta Arrestin,C8orf44-SGK3/SGK3,caspase,Cg,Creb,cytochrome 
C,DBNL,E2f,EPGN,ERK,F2RL1,FSH,G protein 
alphai,Gpcr,HDL,IGF1,INF2,Lh,MAP2K1/2,MAPK10,Mek,MKNK1,NFkB 
(complex),NOL3,p85 (pik3r),PLC,POMC,Ras,Rock,Sapk,SMARCA1,TCR,Tnf 
(family),trypsin
AADAC,AQP7,BAMBI,BRD8,CABLES1,CST6,DIAPH3,Enolase,EVPL,EXOC1,EXOC5,FAM
90A1,FGF5,FGFR1,FGFRL1,GBP1,GPC1,growth factor 
receptor,HP1BP3,HSD11B2,HTRA3,ICA1,KLK1,LGMN,LMNA,MYC,NDUFS2,OSM,PGA
5 (includes others),RARG,SLC16A3,SRC,TAT,TGM2,ZNF423
ADAMTS7,ADCY7,ASGR1,ATXN1,BAI2,C1orf86,C5AR2,CPB2,CRADD,FANCF,FBXL7,FX
N,G0S2,GLS,HCAR3,HNF4A,LACTB,MC3R,NFKBIL1,NPY2R,NPY5R,PEMT,PIK3R5,PPP1
R3C,PTGFR,RB1,SDH,SDHB,SLC10A1,SLC22A18AS,SLC52A1,SYBU,TNF,Ubiquitin,ZFP
64
PKD1L2,SBDS
ADAM11,ADAM23,LGI2
Table S7. Intrinsic subtype concordance between pairs.
Study I Basal-like HER2-Enriched Luminal A Luminal B Normal-like
Basal-like 1 0 0 0 0
HER2-Enriched 0 0 0 0 0
Luminal A 0 0 13 1 1
Luminal B 0 0 1 5 0
Normal-like 0 0 0 0 1
Total 1 0 14 6 2
Study II Basal-like HER2-Enriched Luminal A Luminal B Normal-like
Basal-like 0 0 0 0 0
HER2-Enriched 0 0 0 1 0
Luminal A 0 0 32 6 1
Luminal B 0 0 4 10 0
Normal-like 0 0 2 0 0
Total 0 0 38 17 1
Sample A
     Sample B
Surgery
Diagnosis
Total
1
0
15
6
1
23
Total
0
1
39
14
2
56
Table S8. Top pathways identified in Study II.
Canonical Pathways B-H p-value
IL-17A Signaling in Fibroblasts 0.005
Glucocorticoid Receptor Signaling 0.006
Thrombopoietin Signaling 0.006
CXCR4 Signaling 0.006
ERK5 Signaling 0.006
ILK Signaling 0.006
Prolactin Signaling 0.006
Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes 0.006
PDGF Signaling 0.006
IGF-1 Signaling 0.010
Colorectal Cancer Metastasis Signaling 0.010
Cholecystokinin/Gastrin-mediated Signaling 0.010
IL-17A Signaling in Gastric Cells 0.011
TNFR2 Signaling 0.012
HMGB1 Signaling 0.012
P2Y Purigenic Receptor Signaling Pathway 0.012
PI3K Signaling in B Lymphocytes 0.013
GNRH Signaling 0.013
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 0.013
Aryl Hydrocarbon Receptor Signaling 0.014
April Mediated Signaling 0.015
MIF Regulation of Innate Immunity 0.016
B Cell Activating Factor Signaling 0.016
UVC-Induced MAPK Signaling 0.017
iNOS Signaling 0.017
TNFR1 Signaling 0.019
Endothelin-1 Signaling 0.019
RAR Activation 0.019
Molecular Mechanisms of Cancer 0.019
CD27 Signaling in Lymphocytes 0.019
NRF2-mediated Oxidative Stress Response 0.019
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 0.019
UVB-Induced MAPK Signaling 0.019
IL-2 Signaling 0.019
IL-8 Signaling 0.019
ERK/MAPK Signaling 0.019
ErbB2-ErbB3 Signaling 0.019
EGF Signaling 0.019
ATM Signaling 0.020
CCR5 Signaling in Macrophages 0.021
Estrogen-Dependent Breast Cancer Signaling 0.021
Pyridoxal 5'-phosphate Salvage Pathway 0.021
CD40 Signaling 0.021
Erythropoietin Signaling 0.021
Neurotrophin/TRK Signaling 0.021
IL-10 Signaling 0.021
GDNF Family Ligand-Receptor Interactions 0.021
Chemokine Signaling 0.021
Renal Cell Carcinoma Signaling 0.022
IL-3 Signaling 0.022
Toll-like Receptor Signaling 0.022
JAK/Stat Signaling 0.022
LPS-stimulated MAPK Signaling 0.022
Signaling by Rho Family GTPases 0.024
Ceramide Signaling 0.026
ErbB Signaling 0.028
RANK Signaling in Osteoclasts 0.028
UVA-Induced MAPK Signaling 0.028
TGF-β Signaling 0.028
PPAR Signaling 0.030
IL-1 Signaling 0.030
T Cell Receptor Signaling 0.031
p53 Signaling 0.032
CDK5 Signaling 0.032
HGF Signaling 0.035
Corticotropin Releasing Hormone Signaling 0.035
Role of Tissue Factor in Cancer 0.035
CD28 Signaling in T Helper Cells 0.035
Renin-Angiotensin Signaling 0.035
PKCθ Signaling in T Lymphocytes 0.035
p38 MAPK Signaling 0.039
14-3-3-mediated Signaling 0.039
IL-6 Signaling 0.039
Cdc42 Signaling 0.044
IL-12 Signaling and Production in Macrophages 0.048
Relaxin Signaling 0.048
Molecules
FOS,JUN,CEBPD
FOS,JUN,DUSP1,SGK1,TSC22D3
MYC,FOS,JUN
FOS,JUN,RHOB,EGR1
MYC,FOS,SGK1
MYC,FOS,JUN,RHOB
MYC,FOS,JUN
FOS,JUN,TOB1
MYC,FOS,JUN
FOS,JUN,CYR61
MYC,FOS,JUN,RHOB
FOS,JUN,RHOB
FOS,JUN
FOS,JUN
FOS,JUN,RHOB
MYC,FOS,JUN
FOS,JUN,ATF3
FOS,JUN,EGR1
MYC,FOS,JUN,CEBPD
MYC,FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
MYC,FOS,JUN
FOS,JUN,DUSP1
MYC,FOS,JUN,RHOB
FOS,JUN
FOS,JUN,JUNB
FOS,JUN,RHOB
FOS,JUN
FOS,JUN
FOS,JUN,RHOB
MYC,FOS,DUSP1
MYC,JUN
FOS,JUN
JUN,GADD45B
FOS,JUN
FOS,JUN
PDXK,SGK1
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN,RHOB
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
JUN,GADD45B
FOSB,EGR1
FOS,JUN
FOS,JUN
EGR1,CYR61
FOS,JUN
FOS,JUN
FOS,JUN
MYC,DUSP1
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
FOS,JUN
ID Score Focus Molecules
1 27 12
2 19 9
3 9 5
4 5 3
5 3 2
6 3 1
Table S9. Top networks identified in Stu  
Top Diseases and Functions
Neurological Disease, Cell Death and Survival, Cellular Growth 
and Proliferation
Endocrine System Disorders, Gastrointestinal Disease, 
Metabolic Disease
Cell Morphology, Visual System Development and Function, 
Hereditary Disorder
Gene Expression, RNA Damage and Repair, RNA Post-
Transcriptional Modification
Lipid Metabolism, Small Molecule Biochemistry, Drug 
Metabolism
Cancer, Organismal Injury and Abnormalities, Reproductive 
System Disease
      dy II.
Molecules in Network
Ap1,ATF3,BCR (complex),BHLHE40,C/ebp,Calcineurin 
protein(s),CaMKII,CCL3L3,CYR61,DUSP1,EGR1,ERK1/2,Fcer1,FOS
B,GADD45B,GC-GCR dimer,Gm-csf,HBA1/HBA2,Ige,IL12 
(complex),JINK1/2,JUN/JUNB/JUND,JUNB,MAP2K1/2,Nfat 
(family),PDGF BB,Rar,RASD1,Sapk,SERCA,STAT5a/b,Tgf 
beta,thymidine kinase,thyroid hormone receptor,TSC22D3
Akt,Alp,BTG2,calpain,Cdc2,CEBPD,Cg,Collagen type I,Creb,Cyclin 
A,Cyclin E,E2f,ERK,Fgf,FSH,GNRH,Growth 
hormone,Gsk3,HBB,Hsp27,IL1,Integrin,JUN,LDL,Lh,Mek,Pdgf 
(complex),PDXK,Pkg,Rb,RGS2,RHOB,Rock,SGK1,TOB1
APOLD1,ARHGEF25,ARID3A,CD163,COPS5,DSG3,FBXL18,FN1,FP
R1,IgG,IgG1,Insulin,Jnk,KLK8,KRT13,mir-101,mir-188,miR-532-
5p (and other miRNAs w/seed AUGCCUU),NMDA Receptor,P38 
MAPK,PDPN,PIP5K1B,Pka,PTPN22,RGS1,RNY5,SERPINB7,SF3A3,
SNORD3A,SSB,TGFBI,Tnf (family),TROVE2,VGF,ZNF622
26s Proteasome,ADRB,caspase,CD3,Ck2,Endothelin,estrogen 
receptor,Focal adhesion kinase,FOS,Gpcr,Hdac,Histone 
h3,Histone h4,Hsp70,Igm,IKK 
(complex),Immunoglobulin,Mapk,MYC,NFkB (complex),Nicotinic 
acetylcholine receptor,Notch,PI3K (complex),Pkc(s),Rac,Ras,Ras 
homolog,RNA polymerase 
II,Sos,TCF,TCR,TSH,Ubiquitin,Vegf,ZFP36
ADNP,ALDH1A3,B4GALNT1,CBR3,CTH,GM2A,GOLM1,GSR,HERC
1,HSD17B7,HSD3B2,LECT2,LOC102724428/SIK1,MAN1A2,MAOA
,MC4R,MGST1,MT1A,NDUFA8,NDUFB4,NDUFS7,NEFM,NUCB2,R
ABEP2,RGS7,SCO2,Sf1,STAT,SYNPO,TNF,TPP2,UBC,WBSCR22,W
NT10B,ZFP36L2
NUFIP1,SNORD13
       
Table S10. Top 20 genes identified in Study I and their p-value in Study II.
Accession Symbol Parametric p-value FDR FC Parametric p-value
NM_005252 FOS < 1e-07 < 1e-07 4.00 0.0144
NM_002922 RGS1 < 1e-07 < 1e-07 3.23 0.0041
NM_004417 DUSP1 < 1e-07 < 1e-07 3.13 0.0003
NM_000517 HBA2 < 1e-05 0.003 -2.90 0.1004
NM_000518 HBB < 1e-05 0.006 -2.83 0.6704
NM_000517 HBA2 < 1e-05 0.007 -2.64 0.1004
NM_000558 HBA1 < 1e-04 0.008 -2.39
NM_006732 FOSB < 1e-06 0.001 2.38 0.0014
NR_001571 RNY5 < 1e-04 0.019 -2.15
NM_001964 EGR1 < 1e-06 0.001 2.04 0.4480
NM_001554 CYR61 < 1e-05 0.002 2.04 0.0837
NM_003407 ZFP36 < 1e-07 < 1e-07 2.00 0.0005
NR_006882 SNORD3D < 1e-06 0.001 1.85
NR_001449 TRK1 < 1e-07 < 1e-07 -1.75 0.1566
NM_002228 JUN < 1e-07 < 1e-07 1.69 0.0059
NM_005627 SGK < 1e-06 0.0004 1.64 0.0003
NM_005627 SGK1 < 1e-05 0.002 1.61 0.0003
NR_006881 SNORD3C < 1e-04 0.010 1.61
NR_006880 SNORD3A < 1e-04 0.011 1.61
NM_005627 SGK1 < 1e-04 0.016 1.56 0.0003
STUD  STUDY I
FDR FC
0.194 1.64
0.159 1.37
0.133 1.72
0.333 1.23
0.828 1.06
0.333 1.23
0.138 2.08
0.673 1.11
0.312 1.25
0.133 1.54
0.404 -1.05
0.171 1.33
0.133 1.27
0.133 1.27
0.133 1.27
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